Mr. James Howard-Tripp reports
STAGEZERO LIFE SCIENCES ENTERS EUROPEAN MARKET WITH ONCORE PHARMA AND BODYCHECK NL; MULTI-YEAR AGREEMENT VALUED AT US$40 MILLION
Stagezero Life Sciences Ltd.'s licensing partner, Oncore Pharma, has signed a multiyear agreement with BodyCheck NL for the distribution and sale of ColonSentry throughout the Netherlands, Belgium and Luxembourg.
According to the multiyear agreement, the initial term of six months will be used to implement and launch a sales and marketing campaign in Belgium, the Netherlands and Luxembourg. A minimum of 275,000 ColonSentry diagnostic tests for the early detection of colorectal cancer are anticipated to be analyzed and reported out by Stagezero's state-of-the-art facility in Richmond, Va. The multiyear agreement has a value to Stagezero of $40-million (U.S.).
ColonSentry is Stagezero's proprietary liquid biopsy that uses advanced gene expression (mRNA) technology for the early identification of colorectal cancer.
"Oncore Pharma is moving quickly to use its established relationships in Europe to introduce ColonSentry into markets other than the U.S. and this is just the beginning," said James Howard-Tripp, chairman and chief executive officer of Stagezero. "This is just our initial entry point in the European market and we look forward to gaining experience and building our footprint outside of the U.S. even further in 2020."
"We have a solid partner in BodyCheck NL with their already established network of 'checkpoints' throughout the Netherlands. This is an important initial start for us in Europe; the Netherlands ranks No. 10 and Belgium No. 14 in the world for having the highest colorectal cancer rates in both sexes," said Martin Verronneau, president and chief operating officer of Oncore. "We welcome this opportunity to address the need for early colorectal cancer detection within this population."
About Stagezero Life Sciences Ltd.
Stagezero is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle, its next-generation test, is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.